5.15

2.28% -0.12

Pre-market: 5.28 0.13 +2.52%

Bolt Biotherapeutics Inc (BOLT)

Overview News Price History Financials Discussions Forecast

Bolt Biotherapeutics Inc stock is traded at $5.15, with a volume of 26,225. It is down -2.28% in the last 24 hours and up +2.18% over the past month. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Previous Close:

$5.27

Open:

$5.2

24h Volume:

26,225

Relative Volume:

0.93

Market Cap:

$9.89M

Revenue:

$4.17M

Net Income/Loss:

$-50.71M

P/E Ratio:

-0.3822

EPS:

-13.474

Net Cash Flow:

$-51.40M

1W Performance:

+4.04%

1M Performance:

+2.18%

6M Performance:

-20.48%

1Y Performance:

-55.77%

1-Day Range:

$5.15

$5.45

1-Week Range:

$4.7504

$5.45

52-Week Range:

$4.41

$12.60

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Name

Bolt Biotherapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

650-665-9295

Address

900 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

BOLT's Discussions on Twitter

Compare BOLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BOLT Bolt Biotherapeutics Inc	5.15	10.12M	4.17M	-50.71M	-51.40M	-13.47
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Resumed	H.C. Wainwright	Buy
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-21	Initiated	Guggenheim	Buy
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	SVB Leerink	Outperform
Mar-02-21	Initiated	Stifel	Buy

View All

Bolt Biotherapeutics Inc Stock (BOLT) Latest News

Dec 04, 2025

What technical signals suggest for Bolt Biotherapeutics Inc. stockTrade Entry Report & Free Verified High Yield Trade Plans - Newser

Dec 04, 2025

Will Bolt Biotherapeutics Inc. stock continue dividend increasesWeekly Gains Report & Accurate Entry/Exit Alerts - Newser

Dec 04, 2025

Nov 30, 2025

Revenue per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView

Nov 30, 2025

Nov 29, 2025

Risk Check: Will Bolt Biotherapeutics Inc. stock outperform tech sector in 2025IPO Watch & Safe Swing Trade Setup Alerts - BỘ NỘI VỤ

Nov 29, 2025

Nov 28, 2025

Risk Recap: Why Bolt Biotherapeutics Inc. stock could rally in 2025July 2025 Momentum & Weekly Watchlist for Consistent Profits - moha.gov.vn

Nov 28, 2025

Bolt Biotherapeutics (BOLT) Stock Forecast and Price Target 2025 - MarketBeat

Nov 28, 2025

Nov 27, 2025

Will Bolt Biotherapeutics Inc. stock rally after Fed decisions2025 Growth vs Value & AI Driven Stock Reports - BỘ NỘI VỤ

Nov 27, 2025

Will Bolt Biotherapeutics Inc. (6LP0) stock enhance shareholder valueJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - BỘ NỘI VỤ

Nov 27, 2025

Nov 23, 2025

What analysts say about Bolt Biotherapeutics Inc stockHigh Frequency Trading Trends & Low Risk Trading Plans - earlytimes.in

Nov 23, 2025

Bolt Biotherapeutics (NASDAQ:BOLT) Cut to “Hold” at Zacks Research - Defense World

Nov 23, 2025

Nov 22, 2025